Compare Valero Energy Corporation (VLO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Valero Energy Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Valero Energy Corporation trades at $443.1 (market cap $122.11B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Valero Energy Corporation and Vertex Pharmaceuticals Incorporated are close in size by market cap, and Valero Energy Corporation pays a 1.13% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Valero Energy Corporation for 56 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| VLO | VRTX | |
|---|---|---|
Market Cap | $122.11B | $128.16B |
Volume | 1,826,747 | 806,603 |
Sector | Energy | Health |
52-Week High | $443.80 | $557.96 |
52-Week Low | $156.39 | $407.37 |
Typical Hold Time | 56 Days | 120 Days |
Enterprise Value | $125.59B | $122.29B |
Dividend Yield | 1.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Valero Energy (VLO) trades at $443.80, up 5.86% today and near its 52-week high, supported by bullish technical signals and strong earnings beats. Recent quarters have exceeded EPS expectations, with Q2 2026 EPS of $12.54 beating the $10.11 forecast. The stock shows robust profitability with a 29.31% ROE and trades at a P/E of 17.69, below the sector average. Positive news flow highlights refining margin strength and institutional interest.
The outlook remains positive given earnings momentum and favorable analyst sentiment, though risks include potential diesel export policy changes and volatile energy markets. Revenue is projected to rebound to $139.4B in 2026, driving net income higher. Investors should weigh solid fundamentals against sector-specific headwinds.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
